Table 3 Analysis of cancer specific survival (CSS) in RCC, patients without metastases

Stage II vs. I

4.32

2.13-8.73

< 0.0001

3.11

1.48-6.54

0.003

Stage III vs. I

8.94

5.35-14.93

< 0.0001

4.84

2.66-8.80

< 0.0001

Grading 2 vs. 1

1.42

0.73-2.75

0.302

1.11

0.55-2.23

0.768

Grading 3/4 vs. 1

8.91

4.51-17.59

< 0.0001

2.74

1.26-5.95

0.011

Karnofsky < 80 vs. ≥ 80

3.02

1.66-5.48

0.0003

1.82

0.95-3.51

0.072

Age ≥ 65 years vs. < 65 years

1.50

0.95-2.35

0.081

1.01

0.62-1.65

0.965

Sex (Male vs. Female)

1.16

0.73-1.84

0.527

1.37

0.83-2.24

0.216

Clear cell RCC vs. non clear cell RCC

5.43

1.71-17.24

0.004

2.82

0.87-9.22

0.086

Nuclear EZH2 1-5% vs. 0%

1.16

0.64-2.10

0.615

1.21

0.66-2.21

0.546

Nuclear EZH2 >5-25% vs. 0%

0.57

0.23-1.39

0.215

0.60

0.22-1.59

0.301

Nuclear EZH2 >25-50% vs. 0%

3.44

1.54-7.67

0.003

2.72

1.14-6.50

0.025

Nuclear EZH2 >50% vs. 0%

5.11

1.47-17.76

0.010

2.20

0.28-17.42

0.456